Impavido permitted for treating tropical parasitic disease
The U.S. Food and Drug Administration have finally blown a green light to use Impavido for treating adults suffering with leishmaniasi. This is a tropical disease that has been caused by a parasite that is transmitted through the bites of sand flies. The Americans carry this disease by traveling overseas. The particular drug is specifically produced by the Paladin Therapeutics that is based in Montreal.
To ensure the drug’s safety and effectiveness it was properly evaluated in the clinical trials. The study was conducted over 700 people then only it was approved.
The Impavido's label will have a boxed warning that this medication can harm a developing fetus and pregnant women should avoid it. This drug has common side effects including headache, nausea, vomiting, and diarrhea, loss of appetite, dizziness, and elevated liver enzymes. Also, it has been recommended that this drug should prescribed for uncommon problem only and the patient should be well aware of the side effects.